151.07 +2.03 (1.36%)
After hours: 5:00PM EDT
|Bid||145.00 x 1000|
|Ask||150.19 x 800|
|Day's Range||148.50 - 153.18|
|52 Week Range||72.05 - 158.80|
|Beta (5Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||192.86|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
CAMBRIDGE, Mass., June 02, 2020 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 29, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in May 2020. The employees received, in the aggregate, options to purchase 8,015 shares of Sarepta's common stock, and in the aggregate, 4,015 restricted stock units (“RSUs”). The options have an exercise price of $152.27 per share, which is equal to the closing price of Sarepta's common stock on May 29, 2020 (the “Grant Date”).
Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.
Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.
Sarepta Therapeutics still has a leg up on Dow Jones pharma company Pfizer, analysts said Friday after the latter posted updated results of a gene therapy test and SRPT stock popped.
Pfizer (NYSE: PFE) released fairly promising data from its trial for the gene therapy PF-06939926 in boys with Duchenne muscular dystrophy. In a phase 1b clinical trial, treatment with PF-06939926 resulted in expression of dystrophin, the protein that's missing in patients with Duchenne muscular dystrophy. The three patients given the lower dose had an average of 24% of normal expression of dystrophin in muscle biopsies taken 12 months after treatment with PF-06939926.
(Bloomberg) -- Pfizer Inc.’s experimental gene therapy for Duchenne muscular dystrophy helped boys with the deadly disease, but failed to match benefits previously shown by competitor Sarepta Therapeutics Inc.All nine of the boys, ages 6 to 12, in the early-stage trial started to produce a key protein called dystrophin after receiving the one-time treatment. While patients with DMD don’t normally make any of the protein needed for muscles to work properly, three boys on a higher dose of the gene therapy produced about 52% of normal levels a year after treatment, Pfizer said in a statement.One boy on the higher dose needed platelet transfusion and treatment with Alexion Inc.’s Soliris to boost the number of platelets in his blood after his immune system reacted to the gene therapy. While he fully recovered, the reaction marks the third serious adverse event tied to the treatment after two other patients were hospitalized shortly after infusion. In response to the previous safety concerns, Pfizer adjusted its study to increase monitoring and management, which the company says helped mitigate the most recent reaction.The positive results for Pfizer’s therapy would be “a home run for DMD patients, in a vacuum,” wrote Baird analyst Brian Skorney. He said the update “just looks like a pale comparator to Sarepta’s SRP-9001” as the benefits appear lower than those seen with Sarepta’s therapy, and safety issues raise red flags.Sarepta shares jumped as much as 8.6% Friday, the biggest intraday gain for shares since late March, while Pfizer stock was little changed. Shares of the Cambridge, Massachusetts-based biotech are up 15% in the past year.While analysts had been looking forward to an update on the competitive landscape for DMD gene therapies, comparison remains difficult. While Sarepta has relied on a standard analysis called Western Blot that measures the level of dystrophin expression, Pfizer has opted for different technology. Measured by Pfizer’s test, the average expression of patients on the higher dose was significant compared to a baseline measure, with five of the six boys showing an increase in mini-dystrophin concentration between two and 12 months.The gene therapy’s benefit was also measured through a standard test of movement ability, including things like walking and climbing. While boys in the 7- to 9-year-old range typically start to plateau or lose motor abilities, six patients on Pfizer’s therapy for at least a year posted 3.5-point gains.A low-single-digit improvement in that score would be “somewhat encouraging” for the field, Bernstein analysts said on Thursday, as it would suggest dystrophin production translates to a functional benefit. At a conference in June, Pfizer said two boys in its trial posted a 4.5-point gain one year after treatment.DMD is a genetic disease characterized by progressive muscle degeneration and weakness. It’s the most common form of muscular dystrophy worldwide and affects about 250,000 people in the U.S., mostly boys. Pfizer’s data are being presented at a virtual meeting of the American Society of Gene & Cell Therapy.In the Pfizer study, another exploratory analysis used MRI to show a reduction in fat in the thighs of boys treated at the higher dose after a year of follow-up. That suggests the gene therapy may have improved muscle fiber health and quality, Pfizer said, noting that DMD patients typically lose muscle and gain fatty tissue as the disease progresses. No reduction in fat was seen in patients receiving the lower dose.The New York-based drugmaker plans to start treating patients in a late-stage study in the second half of the year after it gets clearance from the U.S. Food and Drug Administration. The company is neck-and-neck with Cambridge, Massachusetts-based Sarepta, which expects to start a multicountry study later this year after delays. SVB Leerink analyst Joseph Schwartz wrote earlier this month that “investors will likely reward the first company out of the Phase 3 gates.”(Updates with analyst commentary in fourth paragraph, share movement in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
It has been noted ad nauseam that the stock market doesn't appear to reflect the worst economic slowdown since the Great Depression. The Dow Jones Industrial Average is down "only" 17% for the year to date, while the S&P; 500 is off "just" 11%.If that bothers you, don't even look at the Nasdaq Composite. This tech-heavy index of Nasdaq-listed stocks is actually positive, albeit barely, for 2020.Whether share prices adequately discount the potential damage caused by the global lockdown and a prolonged recession is a discussion for another time. Besides, investors usually find it more profitable not to fight the tape.With that in mind, we went searching for the Nasdaq stocks that analysts say have the best prospects for outperformance going forward.We screened the Nasdaq Composite for stocks followed by a minimum of 10 analysts. We further whittled the list down to stocks with an average broker recommendation of Buy or better. S&P; Capital IQ surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.0 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call. Lastly, we dug into research, analysts' estimates and other data on the top-scoring names.The process gave us a host of stocks, from small biotechnology plays to some of the biggest, best-known companies in the world. Have a look at 15 of the best Nasdaq stocks, according to the pros. SEE ALSO: 50 Top Stock Picks That Billionaires Love
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 2:30 p.m. E.T. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease.
(Bloomberg) -- A fresh look at how a handful of patients are faring on Pfizer Inc.’s gene therapy for Duchenne muscular dystrophy will be key for investors in competitor Sarepta Therapeutics Inc.Underwhelming effectiveness or new safety issues in this week’s data could remove an overhang for Sarepta shares, which are on their longest winning streak since November. The update will be important in evaluating the competitive landscape before either company starts pivotal trials, wrote RBC Capital Markets analyst Brian Abrahams.RBC expects Pfizer’s presentation at the virtual meeting of the American Society of Gene & Cell Therapy on Friday could trigger a 5% to 10% move in Sarepta shares. Duchenne muscular dystrophy is the core of the company’s pipeline. The two companies are roughly neck-and-neck in drug development for a one-shot therapy to treat patients with the condition, which is marked by progressive muscle weakness and an early death.“We expect Pfizer’s presentation at ASGCT to show that its program is potentially active, though we also expect it could highlight the comparative disadvantages versus Sarepta’s program,” Abrahams said.Analysts have said commentary on Pfizer’s quarterly earnings call reflected enthusiasm for the program, even though the abstract for the meeting contained no new data. “They believe they have seen signs of consistent efficacy on a variety of measures, including signs of functional improvement in some older boys where one would expect functional decline,” Mizuho analyst Vamil Divan wrote of Pfizer’s stance.The commencement of Sarepta’s Study-301, a planned multicountry trial of its gene therapy with commercial-ready material which is key to securing regulatory approval, is likely to start in the second-half of the year after a few months of delay. While it is unclear when Pfizer could start its pivotal trial in the current environment, SVB Leerink analyst Joseph Schwartz said “investors will likely reward the first company out of the Phase 3 gates.”Shares of Cambridge, Massachusetts-based Sarepta are trading 21% higher than they were 12 months ago, though they remain well off a July peak, as investors await updates for its gene-therapy portfolio. All but one of the 24 analysts tracked by Bloomberg recommend buying shares; the lone skeptic has a hold rating.Options in Sarepta set to expire on Friday show expectations that shares are likely to move about 6% by the end of the week. Pfizer’s anticipated move is more muted with options only implying a 2.4% move over the next five days.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, and Dyno Therapeutics, Inc., a biotech company applying artificial intelligence (AI) to gene therapy, today announced an agreement to develop next-generation Adeno-Associated Virus (AAV) vectors for muscle diseases, using Dyno’s CapsidMap™ platform. AI and machine learning technologies have the potential to deliver enhanced vectors for gene therapies.
Sarepta Therapeutics (SRPT) has reported weaker-than-expected earning results for the first quarter. Specifically, Q1 Non-GAAP EPS of -$1.04 missed Street expectations by $1.75 while GAAP EPS of -$0.23 also fell short by $0.67.Although total product revenue of $100.4M climbed 15.4% year-over-year, it nonetheless missed the Street consensus by $17.78M. Sarepta ended the quarter with a cash position of $2.2 bn.Encouragingly, CEO Doug Ingram revealed that “our placebo-controlled gene therapy clinical trial, study 102, for SRP-9001 is on track to read out in the first quarter of 2021 as anticipated.” SRP-9001 micro-dystrophin is a potential treatment for Duchenne Muscular Dystrophy (DMD), a genetic condition that leads to progressive loss of muscle strength.“Additionally, our process development, assay and manufacturing work for SRP-9001 is progressing and we continue to expect GMP [good manufacturing practice] material to be ready in July” he said.Plus clinical data from the company’s second gene therapy program – SRP-9003 in LGMD2E – is expected in 2Q20 as previously guided.With these comments in mind, Mizuho Securities analyst Difei Yang reiterated her buy rating and $183 price target. “Covid-19 is likely to have some impacts on product sales in FY20 and we believe 2020 revenue guidance is at risk” she warned- particularly for Exondys51.But despite the expected short-term revenue impact from Covid-19, ultimately the analyst “continue[s] to see significant value in Sarepta’s gene therapy pipeline, including SRP-9001.” She sees Covid-19 as having minimal long-term impact to SRPT and therefore maintains her bullish stance.Moreover, Yang believes that the read out for study 102 in 1Q21 could represent an important catalyst for the shares. So far the stock is down just over 5% on a year-to-date basis, and is falling 4% in Thursday’s pre-market trading.Overall, analysts shares Yang’s take on Sarepta, with 12 recent buy ratings vs just 1 hold rating. This gives the stock a firm Strong Buy consensus. The average analyst price target of $199 indicates significant upside potential of 63% from current levels. (See SRPT stock analysis on TipRanks).Related News: Japan Plans To Approve Gilead’s Remdesivir Today- Report AstraZeneca Wins FDA Approval For Diabetes Drug to Treat Heart Failure Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales More recent articles from Smarter Analyst: * Taiwan Semi Has Not Received Any Assurance On US License For Huawei Tech Sale * Buffett’s Berkshire Shaves Off 84% Of Its Goldman Sachs Stake * Apple is Said to Snap Up Startup NextVR For Virtual Reality Content; Top Analyst Sees Buying Opportunity * Carl Icahn Initiates Position in Delek US Holdings, Boosts Occidental Petroleum
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 89.96% and 0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
– Net sales of $100.4 million, a 15% increase over same quarter of prior year – – $2.2 billion of cash on hand to drive clinical programs without distraction from COVID-19.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2020. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days.
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Company and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the Department of Defense’s lead laboratory for medical biological defense research, have entered into a Cooperative Research and Development Agreement (CRADA). The purpose of the CRADA is to jointly identify antisense oligonucleotides using Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) platform with activity against SARS-CoV-2 for the potential treatment of COVID-19.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
"Honest to God, there are dozens of targets we could hit. We can afford to be generous and give a partner like Roche whatever they want," Arrakis CEO Michael Gilman said of the Roche collaboration, in which the privately held startup will help Roche develop drugs that target RNA, the element inside molecules that uses DNA instructions to create proteins. Roche will have exclusive rights to test and commercialize any drug candidates.